Publications

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
Cancer Discov 2017 Nov 3. Epub 2017 Nov 3.
Department of Medical Oncology, Dana-Farber Cancer Institute





Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer.
Cancer Res 2017 Jul 4;77(14):3745-3757. Epub 2017 May 4.
Center for Research on Reproduction & Women's Health, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.


PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.
PLoS Genet 2016 Dec 15;12(12):e1006518. Epub 2016 Dec 15.
Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America.



MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Clin Cancer Res 2016 Feb 19;22(4):935-47. Epub 2015 Oct 19.
Department of Obstetrics and Gynecology, University of Miami Miller School of Medicine, Miami, Florida. Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.

miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Pigment Cell Melanoma Res 2015 Jul 16;28(4):431-41. Epub 2015 May 16.
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.






Oncogenic BRAF-Mediated Melanoma Cell Invasion.
Cell Rep 2016 05 19;15(9):2012-24. Epub 2016 May 19.
Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:


OF